サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1623918

男性性腺機能低下症の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）

Male Hypogonadism Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 170 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
男性性腺機能低下症の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2024年12月31日
発行: Persistence Market Research
ページ情報: 英文 170 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の男性性腺機能低下症の市場規模は、2025年に33億米ドルになるとみられ、2025年～2032年の予測期間に4.6%のCAGRで拡大し、2032年には45億米ドルに達すると予測されています。

男性性腺機能低下症市場は、テストステロン値の低下を特徴とし、身体的、感情的、性的な健康課題につながる状態の診断と治療に焦点を当てています。この市場には、テストステロンレベルを正常に戻し、症状を緩和することを目的とした治療法が含まれます。性腺機能低下症に対する認識の高まり、治療オプションの進歩、男性人口の高齢化などの要因が市場成長の原動力となっています。性腺機能低下症関連疾患の有病率の上昇と相まって、研究開発への投資が拡大していることも、市場拡大をさらに後押ししています。

世界の男性性腺機能低下症市場の成長には、ライフスタイルの変化や高齢化によるテストステロン欠乏症の有病率の上昇など、いくつかの要因が寄与しています。診断技術やテストステロン補充療法、ゴナドトロピン補充療法などの治療法の進歩が市場の需要を後押ししています。性腺機能低下症とその生活の質への影響に対する意識の高まりも、早期診断と治療の採用を促進しています。新興国におけるヘルスケアインフラの拡大と男性の健康への関心の高まりが、市場の成長をさらに後押ししています。

男性性腺機能低下症市場は、治療技術の進歩とヘルスケアへのアクセスの拡大により、大きな成長機会を提供しています。長時間作用型注射剤や経皮パッチなどの薬剤製剤の革新は、市場参入者に新たな道を開きます。遠隔医療やデジタル・ヘルス・ソリューションへの注目が高まることで、診断や治療へのアクセスも向上します。製薬企業とヘルスケアプロバイダーの戦略的提携は、製品開発を加速し、市場開拓を拡大します。

当レポートでは、世界の男性性腺機能低下症市場について調査し、治療別、薬剤タイプ別、疾患タイプ別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 世界経済の見通し

第2章 世界の男性性腺機能低下症市場-エグゼクティブサマリー

第3章 世界の男性性腺機能低下症市場の概要

第4章 世界の男性性腺機能低下症市場の分析と予測、2025年～2032年

  • 世界の男性性腺機能低下症の市場規模と予測、2025年～2032年、治療別
  • 世界の男性性腺機能低下症の市場規模と予測、2025年～2032年、薬剤タイプ別
  • 世界の男性性腺機能低下症の市場規模と予測、2025年～2032年、疾患タイプ別

第5章 北米の男性性腺機能低下症の市場規模と予測、2025年～2032年

第6章 ラテンアメリカの男性性腺機能低下症の市場規模と予測、2025年～2032年

第7章 欧州の男性性腺機能低下症の市場規模と予測、2025年～2032年

第8章 日本の男性性腺機能低下症の市場規模と予測、2025年～2032年

第9章 日本を除くアジア太平洋の男性性腺機能低下症の市場規模と予測、2025年～2032年

第10章 中東・アフリカの男性性腺機能低下症の市場規模と予測、2025年～2032年

第11章 世界の男性性腺機能低下症市場の企業シェア、競合情勢、企業プロファイル

  • 企業シェア分析
  • 競合情勢
  • 企業プロファイル
    • Endo International Plc
    • Eli Lilly and Company Ltd.
    • AbbVie, Inc.
    • Pfizer, Inc.
    • Merck KGaA
    • Allergan Plc
    • Sun Pharmaceutical Industries Limited
    • Ferring B.V.

第12章 調査手法

第13章 二次資料と一次情報

第14章 仮定と頭字語

第15章 免責事項

目次
Product Code: PMRREP22303

Persistence Market Research has recently released a comprehensive report on the global Male Hypogonadism Market, providing an in-depth analysis of key market dynamics, including drivers, emerging trends, opportunities, and challenges. This report delivers detailed insights into the market landscape, enabling stakeholders to make informed decisions.

Key Insights:

  • Male Hypogonadism Market Size (2025E): USD 3.3 Bn
  • Projected Market Value (2032F): USD 4.5 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 4.6%

Male Hypogonadism Market - Report Scope:

The Male Hypogonadism market focuses on the diagnosis and treatment of a condition characterized by low testosterone levels, leading to physical, emotional, and sexual health challenges. The market includes therapies aimed at restoring normal testosterone levels and alleviating symptoms. Factors such as increasing awareness of hypogonadism, advancements in therapeutic options, and an aging male population drive market growth. Growing investments in research and development, coupled with the rising prevalence of hypogonadism-related conditions, further propel market expansion.

Market Growth Drivers:

Several factors contribute to the growth of the global Male Hypogonadism market, including increasing prevalence of testosterone deficiency due to lifestyle changes and aging. Advancements in diagnostic technologies and therapies, such as testosterone replacement therapy and gonadotropin replacement therapy, are bolstering market demand. Rising awareness of hypogonadism and its effects on quality of life is also driving early diagnosis and treatment adoption. The expansion of healthcare infrastructure and increased focus on men's health in emerging economies further support market growth.

Market Restraints:

Despite its growth potential, the Male Hypogonadism market faces several challenges, including the risk of side effects associated with testosterone replacement therapies and stringent regulatory requirements for drug approvals. The stigma around discussing men's health issues and low awareness in developing regions hinder market penetration. High costs of advanced therapies and limited availability of treatment options in remote areas also pose significant barriers.

Market Opportunities:

The Male Hypogonadism market offers substantial growth opportunities driven by advancements in therapeutic technologies and expanding healthcare accessibility. Innovations in drug formulations, such as long-acting injectables and transdermal patches, create new avenues for market players. The increasing focus on telemedicine and digital health solutions also enhances diagnosis and treatment access. Strategic collaborations between pharmaceutical companies and healthcare providers can accelerate product development and expand market reach.

Key Questions Answered in the Report:

  • What are the primary factors driving the global Male Hypogonadism market?
  • Which therapies and drug types are witnessing the highest adoption?
  • How are advancements in diagnostic and therapeutic technologies shaping the market?
  • Who are the leading players in the Male Hypogonadism market, and what strategies are they employing to stay competitive?
  • What are the emerging trends and future prospects for the global Male Hypogonadism market?

Competitive Intelligence and Business Strategy:

Leading companies in the global Male Hypogonadism market, such as Endo International Plc, Eli Lilly and Company Ltd., and Pfizer, Inc., are focusing on product innovation, research, and development to strengthen their market position. These companies are leveraging advancements in drug delivery technologies and expanding their portfolio to include a variety of therapies for hypogonadism. Strategic partnerships with healthcare institutions, regulatory bodies, and distributors enhance market penetration. Emphasizing patient education and awareness campaigns is a key strategy for driving adoption and long-term success.

Key Companies Profiled:

  • Endo International Plc
  • Eli Lilly and Company Ltd.
  • AbbVie, Inc.
  • Pfizer, Inc.
  • Merck KGaA
  • Allergan Plc
  • Sun Pharmaceutical Industries Limited
  • Ferring B.V.
  • Others

Male Hypogonadism Industry Research by Category:

By Therapy:

  • Testosterone Replacement Therapy
  • Gonadotropin Replacement Therapy

By Drug Type:

  • Topical Gels
  • Injectables
  • Transdermal Patches
  • Others

By Disease Type:

  • Klinefelter's Syndrome
  • Pituitary Adenomas
  • Kallmann Syndrome
  • Other Types

By Region:

  • North America
  • Latin America
  • Europe
  • Japan
  • APEJ
  • MEA

Table of Contents

1. Global Economic Outlook

2. Global Male Hypogonadism Market - Executive Summary

  • 2.1. Opportunity Analysis - Male Hypogonadism Market

3. Global Male Hypogonadism Market Overview

  • 3.1. Introduction
    • 3.1.1. Global Male Hypogonadism Market Taxonomy
    • 3.1.2. Global Male Hypogonadism Market Definition
  • 3.2. Global Male Hypogonadism Market Size (US$ Bn ) and Forecast, 2025 - 2032
    • 3.2.1. Global Male Hypogonadism Market Y-o-Y Growth
  • 3.3. Global Male Hypogonadism Market Dynamics
  • 3.4. Supply Chain
  • 3.5. Cost Structure
  • 3.6. Pricing Analysis
  • 3.7. PESTL Analysis
  • 3.8. Product Life Cycle Analysis
  • 3.9. Epidemiology
  • 3.10. List of Distributors
  • 3.11. Key Participants Market Presence (Intensity Map) By Region

4. Global Male Hypogonadism Market Analysis and Forecast 2025 - 2032

  • 4.1. Global Male Hypogonadism Market Size and Forecast By Therapy , 2025 - 2032
    • 4.1.1. Testosterone Replacement Therapy Market Size and Forecast, 2025 - 2032
      • 4.1.1.1. Revenue (US$ Bn ) Comparison, By Region
      • 4.1.1.2. Market Share Comparison, By Region
      • 4.1.1.3. Y-o-Y growth Comparison, By Region
    • 4.1.2. Gonadotropin Replacement Therapy Market Size and Forecast, 2025 - 2032
      • 4.1.2.1. Revenue (US$ Bn ) Comparison, By Region
      • 4.1.2.2. Market Share Comparison, By Region
      • 4.1.2.3. Y-o-Y growth Comparison, By Region
  • 4.2. Global Male Hypogonadism Market Size and Forecast By Drug Type, 2025 - 2032
    • 4.2.1. Topical Gels Market Size and Forecast, 2025 - 2032
      • 4.2.1.1. Revenue (US$ Bn ) Comparison, By Region
      • 4.2.1.2. Market Share Comparison, By Region
      • 4.2.1.3. Y-o-Y growth Comparison, By Region
    • 4.2.2. Injectables Market Size and Forecast, 2025 - 2032
      • 4.2.2.1. Revenue (US$ Bn ) Comparison, By Region
      • 4.2.2.2. Market Share Comparison, By Region
      • 4.2.2.3. Y-o-Y growth Comparison, By Region
    • 4.2.3. Transdermal Patches Market Size and Forecast, 2025 - 2032
      • 4.2.3.1. Revenue (US$ Bn ) Comparison, By Region
      • 4.2.3.2. Market Share Comparison, By Region
      • 4.2.3.3. Y-o-Y growth Comparison, By Region
    • 4.2.4. Others Market Size and Forecast, 2025 - 2032
      • 4.2.4.1. Revenue (US$ Bn ) Comparison, By Region
      • 4.2.4.2. Market Share Comparison, By Region
      • 4.2.4.3. Y-o-Y growth Comparison, By Region
  • 4.3. Global Male Hypogonadism Market Size and Forecast By Disease Type, 2025 - 2032
    • 4.3.1. Klinefelter's Syndrome Market Size and Forecast, 2025 - 2032
      • 4.3.1.1. Revenue (US$ Bn ) Comparison, By Region
      • 4.3.1.2. Market Share Comparison, By Region
      • 4.3.1.3. Y-o-Y growth Comparison, By Region
    • 4.3.2. Pituitary Adenomas Market Size and Forecast, 2025 - 2032
      • 4.3.2.1. Revenue (US$ Bn ) Comparison, By Region
      • 4.3.2.2. Market Share Comparison, By Region
      • 4.3.2.3. Y-o-Y growth Comparison, By Region
    • 4.3.3. Kallmann Syndrome Market Size and Forecast, 2025 - 2032
      • 4.3.3.1. Revenue (US$ Bn ) Comparison, By Region
      • 4.3.3.2. Market Share Comparison, By Region
      • 4.3.3.3. Y-o-Y growth Comparison, By Region
    • 4.3.4. Other Types Market Size and Forecast, 2025 - 2032
      • 4.3.4.1. Revenue (US$ Bn ) Comparison, By Region
      • 4.3.4.2. Market Share Comparison, By Region
      • 4.3.4.3. Y-o-Y growth Comparison, By Region

5. North America Male Hypogonadism Market Size and Forecast, 2025 - 2032

  • 5.1. North America Outlook
  • 5.2. North America Parent Market Outlook
  • 5.3. North America Target Market Outlook
  • 5.4. Revenue (US$ Bn ) Comparison, By Country
    • 5.4.1. US Market Size and Forecast (US$ Bn ), 2025 - 2032
    • 5.4.2. Canada Market Size and Forecast (US$ Bn ), 2025 - 2032
  • 5.5. Revenue (US$ Bn ) Comparison, By Therapy
  • 5.6. Revenue (US$ Bn ) Comparison, By Drug Type
  • 5.7. Revenue (US$ Bn ) Comparison, By Disease Type

6. Latin America Male Hypogonadism Market Size and Forecast, 2025 - 2032

  • 6.1. Latin America Outlook
  • 6.2. Latin America Parent Market Outlook
  • 6.3. Latin America Target Market Outlook
  • 6.4. Revenue (US$ Bn ) Comparison, By Country
    • 6.4.1. Brazil Market Size and Forecast (US$ Bn ), 2025 - 2032
    • 6.4.2. Mexico Market Size and Forecast (US$ Bn ), 2025 - 2032
    • 6.4.3. Rest of Latin America Market Size and Forecast (US$ Bn ), 2025 - 2032
  • 6.5. Revenue (US$ Bn ) Comparison, By Therapy
  • 6.6. Revenue (US$ Bn ) Comparison, By Drug Type
  • 6.7. Revenue (US$ Bn ) Comparison, By Disease Type

7. Europe Male Hypogonadism Market Size and Forecast, 2025 - 2032

  • 7.1. Europe Outlook
  • 7.2. Europe Parent Market Outlook
  • 7.3. Europe Target Market Outlook
  • 7.4. Revenue (US$ Bn ) Comparison, By Country
    • 7.4.1. Germany Market Size and Forecast (US$ Bn ), 2025 - 2032
    • 7.4.2. UK Market Size and Forecast (US$ Bn ), 2025 - 2032
    • 7.4.3. France Market Size and Forecast (US$ Bn ), 2025 - 2032
    • 7.4.4. Spain Market Size and Forecast (US$ Bn ), 2025 - 2032
    • 7.4.5. Italy Market Size and Forecast (US$ Bn ), 2025 - 2032
    • 7.4.6. Rest of Europe Market Size and Forecast (US$ Bn ), 2025 - 2032
  • 7.5. Revenue (US$ Bn ) Comparison, By Therapy
  • 7.6. Revenue (US$ Bn ) Comparison, By Drug Type
  • 7.7. Revenue (US$ Bn ) Comparison, By Disease Type

8. Japan Male Hypogonadism Market Size and Forecast, 2025 - 2032

  • 8.1. Japan Outlook
  • 8.2. Japan Parent Market Outlook
  • 8.3. Japan Target Market Outlook
  • 8.4. Revenue (US$ Bn ), 2025 - 2032
    • 8.4.1. Japan Market Size and Forecast (US$ Bn ), 2025 - 2032
  • 8.5. Revenue (US$ Bn ) Comparison, By Therapy
  • 8.6. Revenue (US$ Bn ) Comparison, By Drug Type
  • 8.7. Revenue (US$ Bn ) Comparison, By Disease Type

9. APEJ Male Hypogonadism Market Size and Forecast, 2025 - 2032

  • 9.1. APEJ Outlook
  • 9.2. APEJ Parent Market Outlook
  • 9.3. APEJ Target Market Outlook
  • 9.4. Revenue (US$ Bn ) Comparison, By Country
    • 9.4.1. China Market Size and Forecast (US$ Bn ), 2025 - 2032
    • 9.4.2. India Market Size and Forecast (US$ Bn ), 2025 - 2032
    • 9.4.3. Thailand Market Size and Forecast (US$ Bn ), 2025 - 2032
    • 9.4.4. Singapore Market Size and Forecast (US$ Bn ), 2025 - 2032
    • 9.4.5. Australia Market Size and Forecast (US$ Bn ), 2025 - 2032
    • 9.4.6. Rest of APEJ Market Size and Forecast (US$ Bn ), 2025 - 2032
  • 9.5. Revenue (US$ Bn ) Comparison, By Therapy
  • 9.6. Revenue (US$ Bn ) Comparison, By Drug Type
  • 9.7. Revenue (US$ Bn ) Comparison, By Disease Type

10. MEA Male Hypogonadism Market Size and Forecast, 2025 - 2032

  • 10.1. MEA Outlook
  • 10.2. MEA Parent Market Outlook
  • 10.3. MEA Target Market Outlook
  • 10.4. Revenue (US$ Bn ) Comparison, By Country
    • 10.4.1. GCC Countries Market Size and Forecast (US$ Bn ), 2025 - 2032
    • 10.4.2. South Africa Market Size and Forecast (US$ Bn ), 2025 - 2032
    • 10.4.3. Israel Market Size and Forecast (US$ Bn ), 2025 - 2032
    • 10.4.4. Rest of MEA Market Size and Forecast (US$ Bn ), 2025 - 2032
  • 10.5. Revenue (US$ Bn ) Comparison, By Therapy
  • 10.6. Revenue (US$ Bn ) Comparison, By Drug Type
  • 10.7. Revenue (US$ Bn ) Comparison, By Disease Type

11. Global Male Hypogonadism Market Company Share, Competition Landscape and Company Profiles

  • 11.1. Company Share Analysis
  • 11.2. Competition Landscape
  • 11.3. Company Profiles
    • 11.3.1. Endo International Plc
    • 11.3.2. Eli Lilly and Company Ltd.
    • 11.3.3. AbbVie, Inc.
    • 11.3.4. Pfizer, Inc.
    • 11.3.5. Merck KGaA
    • 11.3.6. Allergan Plc
    • 11.3.7. Sun Pharmaceutical Industries Limited
    • 11.3.8. Ferring B.V.
  • 11.4. Key takeaways - Male Hypogonadism Market

12. Research Methodology

13. Secondary and Primary Sources

14. Assumptions and Acronyms

15. Disclaimer